

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.

Learn more: [PMC Disclaimer](#) | [PMC Copyright Notice](#)

CELLULAR ONCOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR CELLULAR ONCOLOGY

[Hindawi Limited](#)

[Cell Oncol.](#) 2006; 28(5-6): 247–257.

PMCID: PMC4618222

Published online 2006 Dec 12. doi: [10.1155/2006/846251](https://doi.org/10.1155/2006/846251)

PMID: [17167178](https://pubmed.ncbi.nlm.nih.gov/17167178/)

Promoter Methylation Precedes Chromosomal Alterations in Colorectal Cancer Development

[Sarah Derks](#),¹ [Cindy Postma](#),² [Peter T. M. Moerkerk](#),¹ [Sandra M. van den Bosch](#),¹ [Beatriz Carvalho](#),² [Mario A. J. A. Hermsen](#),³ [Walter Giaretti](#),⁴ [James G. Herman](#),⁵ [Matty P. Weijnenberg](#),⁶ [Adriaan P. de Bruïne](#),¹ [Gerrit A. Meijer](#),² and [Manon van Engeland](#)^{1,*}

Abstract

Background: Colorectal cancers are characterized by genetic and epigenetic alterations. This study aimed to explore the timing of promoter methylation and relationship with mutations and chromosomal alterations in colorectal carcinogenesis. **Methods:** In a series of 47 nonprogressed adenomas, 41 progressed adenomas (malignant polyps), 38 colorectal carcinomas and 18 paired normal tissues, we evaluated promoter methylation status of *hMLH1*, *O⁶MGMT*, *APC*, *p14^{ARF}*, *p16^{INK4A}*, *RASSF1A*, *GATA-4*, *GATA-5*, and *CHFR* using methylation-specific PCR. Mutation status of *TP53*, *APC* and *KRAS* were studied by p53 immunohistochemistry and sequencing of the *APC* and *KRAS* mutation cluster regions. Chromosomal alterations were evaluated by comparative genomic hybridization. **Results:** Our data demonstrate that nonprogressed adenomas, progressed adenomas and carcinomas show similar frequencies of promoter methylation for the majority of the genes. Normal tissues showed significantly lower frequencies of promoter methylation of *APC*, *p16^{INK4A}*, *GATA-4*, and *GATA-5* (*P*-values: 0.02, 0.02, 1.1×10^{-5} and 0.008 respectively). P53 immunopositivity and chromosomal abnormalities occur predominantly in carcinomas (*P* values: 1.1×10^{-5} and 4.1×10^{-10}). **Conclusions:** Since promoter methylation was already present in nonprogressed adenomas without chromosomal alterations, we conclude that promoter methylation can be regarded as an early event preceding *TP53* mutation and chromosomal abnormalities in colorectal cancer development.

Keywords: Colorectal cancer, promoter methylation, genetic alterations, chromosomal instability

Feedback

